Ovarian Cancer Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (PARP, PD-L1, Angiogenesis Inhibitors), By Major Markets (U.S., U.K., Germany, Spain, Italy, France, Japan), And Segment Forecasts, 2016 - 2022

Industry Outlook

The global ovarian cancer drugs market size was valued at USD 1,030 million in 2016. It is expected to exhibit a phenomenal CAGR of 23.7% during the forecast period, with the U.S. at the forefront of the growth. Rising incidence of ovarian cancer owing to growing geriatric population and unhealthy lifestyles is one of the key trends escalating market growth. Besides this, increasing adoption of novel drugs and presence of strong developmental pipeline are estimated positively reinforce ovarian cancer treatment market. 

According to the World Cancer Research Fund International (WCRF), ovarian cancer is the seventh most common cancer in women worldwide and causes more deaths per year than any other gynecological cancer. In 2016, approximately 235,200 new cases and 140,000 deaths were reported worldwide. This disease mainly develops in older women with a peak age of 63 years. Mortality rate fell worldwide in the past decade and is anticipated to continue to decline in the U.S., Europe, and to a smaller degree, in Japan during the forecast period. Growing consumption of contraceptives and declining use of hormonal therapies are resulting in reduced mortality rate due to this cancer.

According to the Centers for Disease Control and Prevention (CDC), ovarian cancer is the tenth most common cancer among women in the U.S. and is the deadliest of all gynecologic malignancies, causing more than 14,000 deaths each year. In 2017, 22,440 patients were diagnosed with ovarian cancer, and 14,080 deaths were reported in the U.S.

Among the major drug classes, PARP inhibitors are likely to contribute to majority of share in the market in 2022, supported by continued uptake of approved drugs and superior efficacy. Surging uptake of checkpoint inhibitors is also projected to benefit the growth of the market.

Therapeutic Class Insights

Until 2014, options available to treat ovarian cancer primarily included chemotherapy, radiation, and surgery and the marketplace was flooded with generics. Ovarian cancer treatment landscape has changed dramatically in the last few years with upswing in the uptake of PARP inhibitors and angiogenesis inhibitors.

For two years post Lynparza’s 2014 launch, AstraZeneca was the only player in the PARP inhibitors market space. Clovis Oncology’s Rubraca was approved in 2016 as a third-line therapy for indication. Tesaro’s Zejula was launched in March 2017 as a maintenance therapy in patients irrespective of BRCA mutation. Among PARP inhibitors, both Zejula and Rubraca have shown strong results during their early launches and compete directly with AstraZeneca’s Lynparza.

Current research in ovarian cancer is focused on using novel treatments such as immunotherapy, targeted therapy, and most importantly combination regimens. Immuno-oncologic agents have shown promising results with improved survival and lower toxicity. However, single-agent response rate of PD-1/ PD-L1 molecules such as Opdivo and Keytruda for ovarian cancer treatment is less than 20.0%. Combination therapies, specifically those including checkpoint inhibitors, are poised to be introduced in the first-line setting to target major unmet needs including overcoming tumour resistance, improving progression free survival, and maintaining quality of life.

Pipeline Insights

Currently, multiple Phase II and III clinical trials evaluating checkpoint inhibitors in combination regimens are ongoing. Unmet needs within the ovarian cancer drugs market present a strong opportunity to develop breakthrough first-in-class therapies. Introduction of non-platinum based PARP inhibitors and VEGF inhibitors in second and third-line settings is changing the treatment paradigm for ovarian cancer dramatically.

Companies are increasingly focusing on development of targeted therapies as novel regimens for ovarian cancer treatment. The future treatment market has a high probability of gaining an array of novel targets and therapy types with multiple first-in-class developments, thus, broadening the scope of potential benefits for patients.

Country Insights

The U.S. dominated the market with more than 45.0% share in 2016. New product launches, increased adoption of novel therapeutics, large target population, and increasing incidence of ovarian cancer are estimated to be the key drivers of this market. Avastin is yet to gain approval as frontline treatment of ovarian cancer in the U.S. and several clinical trials are still being conducted for it in combination with chemotherapeutic agents. In October 2017, the FDA accepted a supplemental biologics license application (sBLA) for Avastin as the first-line treatment for which the decision is expected by June 2018.

China and India are pegged as highly promising countries, offering tremendous growth opportunities for market expansion. Factors such as rising incidence of ovarian cancer, beneficial healthcare reforms, increasing health awareness, low cost base, and lack of regulatory and cultural inhibitions are the primary growth stimulants for the market in India and China.

Ovarian Cancer Drugs Market Share Insights

Some of the key players operating in the market are AstraZeneca, Roche, Tesaro, and Clovis Oncology. Late stage pipeline products of companies such as Pfizer, AbbVie, ImmunoGen, Johnson & Johnson, Boehringer Ingelheim, and Oasmia Pharmaceuticals have also been considered in our market analysis.

Patent expiration and increasing competition from PARP inhibitors are anticipated to impact Avastin’s share in the market. Roche’s Tecentriq-based combination therapy is expected to gain traction as the preferred treatment option in the second-line platinum-sensitive setting. PARP inhibitors are likely to become the preferred maintenance therapy option for advanced stage patients with BRCA mutations. The drug class is projected to drastically improve progression-free survival (PFS) compared to current standard-of-care chemotherapy.

Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, & country levels and provides an analysis of industry trends in each of the sub-segments from 2016 to 2022. For the purpose of this report, Grand View Research has segmented the global ovarian cancer drugs market report on the basis of therapeutic class and country:

• Therapeutic Class Outlook (Revenue, USD Million, 2016 - 2022)

  • PARP Inhibitors

  • Angiogenesis Inhibitors

  • PD-L1 Inhibitors

• Country Outlook (Revenue, USD Million, 2016 - 2022)

  • The U.S.

  • The U.K.

  • France

  • Germany

  • Italy

  • Spain

  • Japan